6 days Ago By ABMN Staff
Renaissance Technologies LLC reduced its position in shares of Acelyrin, Inc. ( NASDAQ:SLRN – Free Report ) by 12.7% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission.
The firm owned 466,921 shares of the company’s stock after selling 67,897 shares during the period. Renaissance Technologies LLC’s holdings in Acelyrin were worth $1,466,000 as of its most recent SEC filing. Several other large investors also recently modified their holdings of the business.
Geode Capital Management LLC raised its position in Acelyrin by 3.5% during the 4th quarter. Geode Capital Management LLC now owns 1,709,086 shares of the company’s stock valued at $5,368,000 after purchasing an additional 57,472 shares during the last quarter.
ADAR1 Capital Management LLC increased its stake in shares of Acelyrin by 731.7% during the fourth quarter. ADAR1 Capital Management LLC now owns 444,967 shares of the company’s stock valued at $1,397,000 after buying an additional 391,467 shares during the period.
Wellington Management Group LLP bought a new position in shares of Acelyrin during the fourth quarter valued at approximately $567,000. ExodusPoint Capital Management LP bought a new position in shares of Acelyrin during the fourth quarter valued at approximately $423,000. Finally, Franklin Resources Inc.
lifted its stake in Acelyrin by 36.9% in the third quarter. Franklin Resources Inc.
now owns 128,591 shares of the company’s stock worth $634,000 after acquiring an additional 34,642 shares during the period. 87.31% of the stock is owned by institutional investors.
Analyst Ratings Changes Several research analysts have commented on SLRN shares. HC Wainwright decreased their price objective on shares of Acelyrin from $8.00 to $6.
00 and set a “neutral” rating for the company in a report on Tuesday, January 7th. Citigroup decreased their price target on shares of Acelyrin from $6.00 to $3.
00 and set a “neutral” rating for the company in a research note on Tuesday, January 7th. Three research analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. Based on data from MarketBeat, Acelyrin presently has a consensus rating of “Hold” and an average target price of $9.
60. Acelyrin Trading Up 0.5 % Shares of SLRN stock opened at $2.
18 on Tuesday. The company’s fifty day moving average price is $2.47 and its 200-day moving average price is $3.
32. The stock has a market cap of $219.98 million, a PE ratio of -0.
89 and a beta of 1.12. Acelyrin, Inc.
has a 12 month low of $1.85 and a 12 month high of $7.25.
Acelyrin ( NASDAQ:SLRN – Get Free Report ) last announced its quarterly earnings data on Wednesday, March 19th. The company reported ($0.79) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.
86) by $0.07. On average, sell-side analysts forecast that Acelyrin, Inc.
will post -2.53 earnings per share for the current fiscal year. Insider Activity at Acelyrin In other Acelyrin news, CEO Mina Kim sold 17,986 shares of the firm’s stock in a transaction dated Monday, March 17th.
The shares were sold at an average price of $2.74, for a total transaction of $49,281.64.
Following the completion of the sale, the chief executive officer now directly owns 671,753 shares in the company, valued at approximately $1,840,603.22. This trade represents a 2.
61 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink . 13.
60% of the stock is owned by corporate insiders. Acelyrin Profile ( Free Report ) Acelyrin, Inc, a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis.
Featured Stories Want to see what other hedge funds are holding SLRN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Acelyrin, Inc. ( NASDAQ:SLRN – Free Report ).
Receive News & Ratings for Acelyrin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acelyrin and related companies with MarketBeat.com's FREE daily email newsletter ..
